

# Fabio Fimiani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2297474/publications.pdf>

Version: 2024-02-01

38  
papers

1,336  
citations

393982

19  
h-index

344852

36  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2368  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry. <i>Journal of Public Health</i> , 2022, 44, 586-594.	1.0	12
2	Diagnosis and Management of Cardiovascular Involvement in Friedreich Ataxia. <i>Heart Failure Clinics</i> , 2022, 18, 31-37.	1.0	12
3	The Risk of Sudden Unexpected Cardiac Death in Children. <i>Heart Failure Clinics</i> , 2022, 18, 115-123.	1.0	16
4	The Biological Role of Vitamins in Athletes' Muscle, Heart and Microbiota. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1249.	1.2	27
5	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 832-841.	0.8	23
6	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 904.	1.2	32
7	Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. <i>Frontiers in Pediatrics</i> , 2021, 9, 632293.	0.9	43
8	Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. <i>Atherosclerosis Plus</i> , 2021, 43, 7-9.	0.3	5
9	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 381.	1.2	12
10	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 151-161.	0.6	53
11	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	0.8	35
12	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. <i>Heart Failure Clinics</i> , 2021, 18, 177-188.	1.0	14
13	Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. <i>Diagnostics</i> , 2021, 11, 2144.	1.3	11
14	MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. <i>Neurology International</i> , 2021, 11, 230-254.	0.2	1
15	760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
16	785 Sodium-glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
17	Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 556-558.	0.8	39
18	Childhood obesity: an overview of laboratory medicine, exercise and microbiome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1385-1406.	1.4	11

#	ARTICLE	IF	CITATIONS
19	Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease. <i>Cardiology Clinics</i> , 2020, 38, 575-588.	0.9	5
20	Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6462.	1.8	38
21	Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 173-180.	0.8	31
22	Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9424.	1.2	23
23	Methicillin-Resistant <i>Staphylococcus aureus</i> : Risk for General Infection and Endocarditis Among Athletes. <i>Antibiotics</i> , 2020, 9, 332.	1.5	8
24	Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. <i>BioFactors</i> , 2020, 46, 367-380.	2.6	46
25	Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. <i>Current Vascular Pharmacology</i> , 2020, 18, 294-301.	0.8	8
26	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	0.7	20
27	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. <i>Journal of Electrocardiology</i> , 2019, 57, 44-54.	0.4	7
28	Laboratory medicine: health evaluation in elite athletes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1450-1473.	1.4	25
29	Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. <i>Internal and Emergency Medicine</i> , 2019, 14, 621-625.	1.0	37
30	Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 83-90.	0.6	13
31	Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 75-77.	0.6	34
32	Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. <i>Angiology</i> , 2018, 69, 103-112.	0.8	8
33	From Femoral to Radial Approach in Coronary Intervention. <i>Angiology</i> , 2017, 68, 281-287.	0.8	21
34	The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-13.	1.4	173
35	Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target. <i>Current Vascular Pharmacology</i> , 2017, 15, 404-415.	0.8	28
36	Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on $\beta_1$ and $\beta_2$ -adrenergic receptors polymorphisms?. <i>International Journal of Cardiology</i> , 2015, 199, 189-192.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. Current Atherosclerosis Reports, 2014, 16, 435.	2.0	413
38	Adipose tissue and vascular inflammation in coronary artery disease. World Journal of Cardiology, 2014, 6, 539.	0.5	42